To assess whether our in vitro results could be confirmed in in vivo lymphoma models, we used a PDX mouse model harboring a double MYC and BCL-2 rearrangement and a 17p deletion (TP53 loss) [42]. This evidence concerns the gene BCL2 and lymphoma.